{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:08:59Z","timestamp":1793470139590,"version":"4.5.0"},"reference-count":13,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kite, a Gilead Company"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2024,8,23]]},"DOI":"10.1080\/10428194.2024.2353877","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:37:36Z","timestamp":1716554256000},"page":"1438-1447","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of patients aged \u226526 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials"],"prefix":"10.1080","volume":"65","author":[{"given":"Monique C.","family":"Minnema","sequence":"first","affiliation":[{"name":"University Medical Center Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Yin","sequence":"additional","affiliation":[{"name":"Medidata Solutions, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruthanna","family":"Davi","sequence":"additional","affiliation":[{"name":"Medidata Solutions, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[{"name":"PRECISIONheor, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Park","sequence":"additional","affiliation":[{"name":"PRECISIONheor, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Itani","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsveta","family":"Hadjivassileva","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Gabriel","family":"Castaigne","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Damico Khalid","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Acute Lymphocytic Leukemia (ALL) SEER 5-year relative survival rates. 2013\u20132019. 2023. [accessed May 2023]. seer.cancer.gov\/statistics."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_3_5_5_1","unstructured":"KYMRIAH (tisagenlecleucel) [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2020."},{"key":"e_1_3_5_6_1","unstructured":"KYMRIAH (tisagenlecleucel). [Summary of product characteristics]. Dublin Ireland: Novartis Europharm Limited; 2021."},{"key":"e_1_3_5_7_1","unstructured":"TECARTUS\u00ae (brexucabtagene autoleucel.) [prescribing information]. Santa Monica (CA): Kite Pharma Inc; 2021."},{"key":"e_1_3_5_8_1","unstructured":"TECARTUS\u00ae. (brexucabtagene autoleucel) [summary of product characteristics]. Amsterdam The Netherlands: Kite Pharma EU B.V.; 2023."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01379-0"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02662-3"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7010"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2353877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T07:29:11Z","timestamp":1727767751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2353877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,8,23]]}},"alternative-id":["10.1080\/10428194.2024.2353877"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2353877","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}